In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability

Bibliography

• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Tox 1992;22:1-21
   PubMed Web of Science ®Google Scholar
• Pelkonen O. Human CYPs: in vivo and clinical aspects. Drug Metab Rev 2002;34:37-46
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callahan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath GH. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33
   PubMed Web of Science ®Google Scholar
• Zlokarnik G, Grootenhuis PDJ, Watson JB. High throughput P450 screens in early drug discovery. Drug Discov Today 2005;10:1443-50
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure AUC i/AUC ratios. Drug Metab Dispos 2004;32:1201-8
   PubMed Web of Science ®Google Scholar
• Foti RS, Wienkers LC, Wahlstrom JL. Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen 2010;13:145-58
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Lin JH. Screening of drug candidates for their drug–rug interaction potential. Curr Opin Chem Biol 2001;5:396-401
   PubMed Web of Science ®Google Scholar
• Brodie BB, Axelrod J, Cooper JR, et al. Detoxication of drugs and other foreign compounds by liver microsomes. Science 1955;121:603-4
   PubMed Web of Science ®Google Scholar
• Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-10
   PubMedGoogle Scholar
• Kumar V, Rock DA, Warren CJ, et al. Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 2006;34:1903-8
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Tucker J, Trigg S, et al. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33:1700-7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000;28:1493-504
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Donato MT, Castell JV, et al. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 2004;5:443-62
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–oward a consensus. Pharm Res 2001;18:1071-80
   PubMedGoogle Scholar
• Reddy A, Heimbach T, Freiwald S, et al. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal 2005;37:319-26
   PubMed Web of Science ®Google Scholar
• Rhodes SP, Otten JN, Hingorani GP, et al. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. J Pharmacol Toxicol Methods 2011;63:223-6
   PubMed Web of Science ®Google Scholar
• Pillai VC, Strom SC, Caritis SN, et al. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. J Pharm Biomed Anal 2013;74:126-32
   PubMed Web of Science ®Google Scholar
• Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000;455:29-60
   PubMed Web of Science ®Google Scholar
• Sakura A, Suzuki S, Satoh T. Improvement of the Ames test using human liver S9 preparation. In: Yan Z, Caldwell G, editors. Optimization in drug discovery: in vitro methods. Methods Pharmacol Toxicol. Humana Press, New York; 2004. p. 325-36
   Google Scholar
• Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:48-57
   PubMed Web of Science ®Google Scholar
• Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91:1923-35
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Ueng YF, Shimada T, et al. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH—cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 1995;34:8380-9
   PubMed Web of Science ®Google Scholar
• Schrag ML, Wienkers LC. Topological alteration of the CYP3A4 active site by the divalent cation Mg2+. Drug Metab Dispos 2000;28:1198-201
   PubMed Web of Science ®Google Scholar
• Hickman D, Wang JP, Wang Y, et al. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998;26:207-15
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Chang SY, Zhang H, et al. Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab Dispos 2007;35:1990-5
   PubMed Web of Science ®Google Scholar
• Forrester LM, Henderson CJ, Glancey MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992;281:661-7
   PubMed Web of Science ®Google Scholar
• Hummel MA, Tracy TS, Hutzler JM, et al. Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9. J Biomol Screen 2006;11:303-9
   PubMed Web of Science ®Google Scholar
• Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003;31(5):606-11
   PubMed Web of Science ®Google Scholar
• Foti RS, Wahlstrom JL. CYP2C19 Inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 2008;36:523-8
   PubMed Web of Science ®Google Scholar
• Lu AYH, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003;31:345-50
   PubMed Web of Science ®Google Scholar
• Sai Y, Dai R Yang TJ, et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000;20:327-43
   Google Scholar
• Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8
   PubMed Web of Science ®Google Scholar
• Ong CE, Coulter S, Birkett DJ, et al. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000;50:573-80
   PubMed Web of Science ®Google Scholar
• Galetin A, Ito K, Hallifax D, et al. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005;314:180-90
   PubMed Web of Science ®Google Scholar
• Friden M, Vanaja K, Nandi VN. Drug-drug interactions of antiinfective drugs: utility of fluorescence CYP inhibition assays in drug discovery. Drug Metabol Drug Interact 2006;21:163-85
   PubMedGoogle Scholar
• Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats for in vitro drug metabolism assays using Vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 2005;10:56-66
   PubMed Web of Science ®Google Scholar
• Cali JJ, Ma D, Sobol M, et al. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2006;2:629-45
   PubMed Web of Science ®Google Scholar
• Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001;391:49-55
   PubMed Web of Science ®Google Scholar
• Jushchyshyn MI, Hutzler JM, Schrag ML, et al. Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome B5 directly induces positive cooperativity. Arch Biochem Biophys 2005;438:21-8
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, et al. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2651-8
   PubMed Web of Science ®Google Scholar
• He F, Bi HC, Xie ZY, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 2007;21:635-43
   PubMed Web of Science ®Google Scholar
• Hatakeyama T, Chen DL, Ismagilov RF. Microgram-scale testing of reaction conditions in solution using nanoliter plugs in microfluidics with detection by MALDI-MS. J Am Chem Soc 2006;128:2518-19
   PubMed Web of Science ®Google Scholar
• Fung EN, Chu I, Li C, et al. Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system. Rapid Commun Mass Spectrom 2003;17:2147-52
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Uusitalo J, Jalonen J, et al. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005;24:123-32
   PubMed Web of Science ®Google Scholar
• Tolonen A, Petsalo A, Turpeinen M, et al. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007;42:960-6
   PubMed Web of Science ®Google Scholar
• Kozakai K, Yamada Y, Oshikata M, et al. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metab Pharmacokinet 2012;27:520-9
   PubMed Web of Science ®Google Scholar
• Di Marco A, Marcucci I, Verdirame M, et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab Dispos 2005;33:349-58
   PubMed Web of Science ®Google Scholar
• Di Marco A, Cellucci A, Chaudhary A, et al. High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. Drug Metab Dispos 2007;35:1737-43
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, et al. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 2004;279:9497-503
   PubMed Web of Science ®Google Scholar
• Wester MR, Yano JK, Schoch GA, et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 2004;279:35630-7
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, et al. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 2004;279:38091-4
   PubMed Web of Science ®Google Scholar
• Yano JK, Hsu MH, Griffin KJ, et al. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 2005;12:822-3
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006;281:7614-22
   PubMed Web of Science ®Google Scholar
• Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 2007;282:14348-55
   PubMed Web of Science ®Google Scholar
• Smith BD, Sanders JL, Porubsky PR, et al. Structure of the human lung cytochrome P450 2A13. J Biol Chem 2007;282:17306-13
   PubMed Web of Science ®Google Scholar
• Czodrowski P, Kriegl JM, Scheuerer S, et al. Computational approaches to predict drug metabolism. Expert Opin Drug Metab Toxicol 2009;5:15-27
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Ekins S. Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev 2002;54:367-83
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 1999;290:429-38
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 2000;28:94-1002
   Web of Science ®Google Scholar
• Sciabola S, Morao I, de Groot MJ. Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability. J Chem Inf Model 2007;47:76-84
   PubMed Web of Science ®Google Scholar
• Freitas RF, Bauab RL, Montanari CA. Novel application of 2D and 3D-similarity searches to identify substrates among cytochrome P450 2C9, 2D6, and 3A4. J Chem Inf Model 2010;50:97-109
   PubMed Web of Science ®Google Scholar
• De Graaf C, Pospisil P, Pos W, et al. Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J Med Chem 2005;48:2308-18
   PubMed Web of Science ®Google Scholar
• De Graaf C, Oostenbrink C, Keizers PHJ, et al. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem 2006;49:2417-30
   PubMed Web of Science ®Google Scholar
• De Rienzo F, Fanelli F, Menziani MC, et al. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 2000;14:93-116
   PubMed Web of Science ®Google Scholar
• Wei DQ, Wang JF, Chen C, et al. Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett 2008;15:27-32
   PubMed Web of Science ®Google Scholar
• Yu J, Paine M.J, Marechal JD, et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos 2006;34:1386-92
   PubMed Web of Science ®Google Scholar
• Locuson CW, Gannett PM, Ayscue R, et al. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem 2007;50:1158-65
   PubMed Web of Science ®Google Scholar
• Vasanthanathan P, Taboureau O, Oostenbrink C, et al. Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques. Drug Metab Dispos 2009;37:658-64
   PubMed Web of Science ®Google Scholar
• Harris DL, Park JY, Gruenke L, et al. Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state. Proteins 2004;55:895-914
   PubMed Web of Science ®Google Scholar
• Wang JF, Wei DQ, Li L, et al. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun 2007;355:513-19
   PubMed Web of Science ®Google Scholar
• Wang JF, Zhang CC, Wei DQ. Docking and molecular dynamics studies on CYP2D6. Chin Sci Bull 2010;55:1877-80
   Web of Science ®Google Scholar
• Dudek AZ, Arodz T, Galvez J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb Chem High Throughput Screen 2006;9:213-28
   PubMed Web of Science ®Google Scholar
• Livingstone DJ. The characterization of chemical structures using molecular properties. A survey. J Chem Inf Comput Sci 2000;40:195-209
   PubMedGoogle Scholar
• Zheng M, Luo X, Shen Q, et al. Site of metabolism prediction for six biotransformations mediated by cytochromes P450. Bioinformatics 2009;25:1251-8
   PubMed Web of Science ®Google Scholar
• Ekins S, Berbaum J, Harrison RK. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab Dispos 2003;31:1077-80
   PubMed Web of Science ®Google Scholar
• Leong MK, Chen YM, Chen TH. Prediction of human cytochrome P450 2B6-substrate interactions using hierarchical support vector regression approach. J Comput Chem 2009;30:1899-909
   PubMed Web of Science ®Google Scholar
• Vasanthanathan P, Hritz J, Taboureau O, et al. Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands. J Chem Inf Model 2009;49:43-52
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Drug Discov 2006;6:140-8
   Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Obach RS, et al. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003;4:423-59
   PubMed Web of Science ®Google Scholar
• Obach RS. Predicting clearance in humans from in vitro data. Curr Top Med Chem 2011;11:334-9
   PubMed Web of Science ®Google Scholar
• Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997;29:891-922
   PubMed Web of Science ®Google Scholar
• Zahlten RN, Stratman FW. The isolation of hormone-sensitive rat hepatocytes by a modified enzymatic technique. Arch Biochem Biophys 1974;163:600-8
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-411
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998;87:1184-9
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000;17:336-43
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473-86
   PubMed Web of Science ®Google Scholar
• Ito K, Hallifax D, Obach RS, et al. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005;33:837-44
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-7
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, et al. Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-75
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 2007;35:246-55
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Boldt S, Kish M, et al. Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008;36:1971-4
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Hurst S, Plowchalk D, et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009;37:1658-66
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22
   PubMed Web of Science ®Google Scholar
• Kosugi Y, Hirabayashi H, Igari T, et al. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 2012;42:127-38
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Duan SX, et al. In vitro prediction the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;4:1222-7
   Google Scholar
• von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Thummel KE, Shen DD, et al. Inhibition of cytochrome P450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180-7
   PubMed Web of Science ®Google Scholar
• Houston JB, Galetin A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 2003;35:393-415
   PubMed Web of Science ®Google Scholar